Estramustine resistance

General Pharmacology

Volumn 33, Issue 2, 1999, Pages 107-113

  Sangrajrang, Suleeporn ^a   Calvo, Fabien ^a   Fellous, Arlette ^a  

^a Molecular genetic Institute   (France)

Author keywords

Drug resistance; Estramustine; Tau; Tubulin expression

Indexed keywords

ESTRAMUSTINE; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE PROTEIN; TAX PROTEIN; TUBULIN;

ADAPTATION; ADVANCED CANCER; CELL DEATH; CELL LINE; DRUG PROTEIN BINDING; DRUG RESISTANCE; GLIOMA CELL; HUMAN; IN VITRO STUDY; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIZATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; PROSTATIC NEOPLASMS; RATS; TAU PROTEINS; TUBULIN;

EID: 0032809448     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00272-9     Document Type: Review

References (73)

1. Banerjee A., Roach M.C., Trcka P., Luduena R.F. Increased microtubule assembly in bovine brain tubulin lacking type III isotype of β-tubulin. J Biol Chem. 265:1990;1794-1799.
2. Bergenheim A.T., Gunnarsson P.O., Edman K., von Schoultz E., Hariz M.I., Henriksson R. Uptake and retention of estramustine and the presence of estramustine-binding protein in malignant brain tumors in humans. Br J Cancer. 67:1993;358-361.
3. Bergenheim A.T., Elfverson J., Gunnarsson P.O., Hartman M., Henriksson R. Cytotoxicity effect and uptake of estramustine in a rat glioma model. Int J Oncol. 5:1994;293-299. a.
4. Bergenheim A.T., Hartman M., Bergh J., Vridderheim P.A., Henriksson R. Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells. J Clin Oncol. 22:1994;45-53. b.
5. Bergenheim A.T., Olofsson A., Stahl A. Prognosis implications of estramustine-binding protein in astrocytoma. Int J Cancer. 7:1995;349-352. a.
6. Bergenheim A.T., Zackrisson B., Elfverson J., Roos G., Henriksson R. Radiosensitizing effect of estramustine in glioma in vitro and in vivo. Neurooncol. 23:1995;191-200. b.
7. Biernat J., Gustke N., Drewes G., Mandelkow E.M., Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules. distribution between PHF-like immunoreactivity and microtubule binding Neuron. 11:1993;153-163.
8. Björk P., Forsgren B., Gustafsson J.A., Pousette A., Högberg B. Partial characterization and "quantitation" of a human prostatic estramustine binding proteins. Cancer Res. 42:1982;1935-1942.
9. Björk P., Borg A., Fernö M., Nilsson S. Expression and partial characterization of estramustine-binding protein in human breast cancer and malignant melanoma. Anticancer Res. 11:1991;1173-1182.
10. Björk P., Issacs J.T., Hartley-Asp B. Estramustine binding protein (EMBP) in rat R3327 Dunning tumors. partial characterization and effect of hormonal withdrawal, hormonal replacement and cytotoxic treatment on its expression Prostate. 18:1994;181-200.
11. Boggs B.A., Gonzalez-Garay M.L., O'Brien W.E., Barlow S.B., Cabral F. Mechanisms of cellular resistance to drugs that target microtubules. Cellular Pharmacol. 1:1993;S95-S101.
12. Boucher D., Larcher J.C., Gros F., Denoulet P. Polyglutamylation of tubulin as a progressive regulator of in vitro interactions between the microtubule-associated protein Tau and tubulin. Biochemistry. 33:1994;12471-12477.
13. Cabral F., Sobel M.E., Gottesman M.M. CHO mutants resistant to colchicine, colcemid, or grisefulvin have an altered β-tubulin. Cell. 20:1980;26-36.
14. Carles J., Domenech M., Gelabert-Mas A., Nogue M., Tabernero J.M., Arcusa A., Guasch I., Miguel A., Ballesteros J.J., Fabregat X. Phase II study estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol. 37:1998;187-191.
15. Eddé B., Rossier J., Le Caer J.P., Desbruyéres E., Gros F., Denoulet P. Glutamylation, a new posttranslation modification of alpha-tubulin. Science. 247:1990;83-85.
16. Eipper B.A. Rat brain microtubule protein. purification and determination of covalently bound phosphate and carbohydrate Proc Natl Acad Sci USA. 69:1972;2283-2287.
17. Eklöv S., Essand M., Carlsson J., Nilsson S. Radiation sensitization by estramustine. studies in cultured human prostatic cancer cells Prostate. 21:1992;287-295.
18. Flüchter S.H., Nelde H.J., Björk P., Muntzing J., Bichler K.H. Effect of treatment on the expression of estramustine-binding protein (EMBP) in prostatic cancer patients. an imunohistochimical study Prostate. 14:1989;27-43.
19. Forsgren B., Björk P. Specific binding of estramustine to prostatic proteins. Urology. 23(suppl. 6):1984;34-38.
20. Forsgren B., Björk P., Carlström K., Gustafsson J.-A., Pousette A., Högberg B. Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivate of estradiol-17β Proc Natl Acad Sci USA. 76:1979;3149-3153.
21. Friden B., Rutberg M., Deinum J., Wallin M. The effect of estramustine derivatives on microtubule assembly in vitro on the charge of the substituent. Biochem Pharmacol. 42:1991;997-1006.
22. Garcia de Ancos J., Correas I., Avila J. Differences in microtubule binding and self-association abilitie of bovine brain tau isoforms. J Biol Chem. 268:1993;7976-7982.
23. Geyp M., Ireland C.M., Pittman S.M. Resistance to apoptotic cell death in drug resistant T cell leukemia cell line. Leukemia. 10:1996;447-455.
24. Goedert M., Spillantini M.G., Potier M.C., Ulrich J., Crowther R.A. Cloning and sequencing of the cDNA encoding an isoform of tau containing four tandem repeats. differential expression of tau proteine mRNA in humain brain EMBO J. 8:1989;393-399.
25. Goedert M., Spillantini M.G., Cairns N.J., Crowther R.A. Tau protein of Alzheimer paired helical filament. abnormal phosphorylation of all six brain isoforms Neuron. 8:1992;159-168.
26. Gottesman M., Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 263:1988;12163-12166.
27. Gunnarsson P.O., Andersson S.B., Johansson S.A., Nilsson T., Plym-Forshell G. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. Eur J Pharmacol. 26:1984;113-119.
28. Groupe European du Cancer du Sein, Essai clinique du phénol bis(2-chloroéthy) carbamate d'oestradiol dans le cancer mamaire en phase avancé Eur J Cancer. 5:1969;1-4.
29. Heyns W., Moor P. Prostatic binding protein. a steroid-binding protein secreted by rat prostate Eur J Biochem. 78:1977;221-230.
30. Heyns W., Peeters B., Mous J., Rombants W., DeMoor P. Purification and characterisation of prostatic binding protein and its subunits. Eur J Biochem. 89:1978;181-186.
31. Hudes G.R., Nathan F., Khater C.et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormonorefractory prostate cancer. J Clin Oncol. 15:1997;3156-3163.
32. Kosik K.S., Orecchio L.D., Bakalis S., Neve R.L. Developmentally regulated expression of specific tau sequences. Neuron. 2:1989;1389-1397.
33. Krauhs E., Little M., Kempf T., Hofer-Warbinek R., Ade W., Ponstingl H. Complet amino acid sequence of β-tubulin from porcine brain. Proc. Natl Acad Sci USA. 78:1981;4156-4160.
34. Laing N., Dahllöf B., Hartley-Asp B., Ranganathan S., Tew K.D. The interaction of estramustine with tubulin isotypes. Biochemistry. 36:1997;871-878.
35. Laing N.M., Belinsky M.G., Kruh G.D., Bell D.W., Boyd J.T., Barone L., Testa J.R., Tew K.D. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. 58:1998;1332-1337.
36. Larcher J.C., Boucher D., Lazereg S., Gros F., Denoulet P. Interaction of kinesin motor domains α- and β-tubulin subunits at a Tau-independent binding site. regulation by polyglutamylation J Biol Chem. 271:1996;22117-22124.
37. Lee G., Rook S.L. Expression of tau protein in non-neuronal cells. microtubule binding and stabilization J Cell Sci. 102:1992;227-237.
38. Lindberg B. Treatment of rapidly progressing prostatic carcinoma with estracyt. J Urol. 108:1972;303-306.
39. Loverstone S., Hartley C.L., Pearce J., Anderton B.H. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells. the effects on the organization and stability of microtubules Neuroscience. 73:1996;1145-1157.
40. Moraga D., Rivas-Berrios A., Farias G., Wallin M., Maccioni R.B. Estramustine-phosphate binds to a tubulin binding domain on microtubule-associated protein MAP2 and Tau. Biochim Biophys Acta. 1121:1992;97-103.
41. Nunez J. Differential expression of microtubule components during brain development. Dev Neurosci. 8:1986;125-141.
42. Ohta S., Nishio K., Kubota N., Ohmori T., Funayama Y., Ohira T., Nakajima H., Adachi M., Saijo N. Characterization of a taxol-resistant human small-cell lung cancer cell line. Cancer Res. 85:1994;290-297.
43. Olmsted J.B., Lyon H.D. A microtubule-associated protein specific to differenciated neuroblastoma cells. J Biol Chem. 256:1981;3507-3511.
44. Olmsted J.B. Non-motor microtubule-associated proteins. Curr Opin Cell Biol. 3:1991;52-58.
45. Panda D., Miller H.P., Banerjee A., Luduena R.F., Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA. 91:1994;11358-11362.
46. Panda D., Miller H.P., Islam K., Wilson L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin. a possible mechanistic basis for its antitumor action Proc Natl Acad Sci USA. 94:1997;10560-10564.
47. Piepmeier J.M., Keefe D.L., Weinstein M.A., Yoshida D., Zielinski J., Lin T.T., Chen Z., Naftolin F. Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synthesis and alter morphology in cultured human glioblastoma cells. Neurosurg. 32:1993;422-431.
48. Pienta K.J., Lehr J.E. Inhibition of prostate cancer growth by estramustine and etoposide. evidence for interaction at the nuclear matrix J Urol. 149:1993;1622-1625.
49. Pienta K.J., Redman B.G., Hussain M., Cunnings C., Ester P.F., Appel C., Flaherty L.E. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 12:1994;2005-2012.
50. Plym-Forshell G., Nilsson H. The distribution of radioactivity after administration of labelled estramustine phosphate (Estracyt), estradiol-17β-phosphate and estradiol to rats. Acta Pharmacol Toxicol. 35(suppl. 1):1974;28.
51. Ranganathan S., Dexter D.W., Benetatos C.A., Chapman A.E., Tew K.D., Hudes G.R. Increase of βIII and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 56:1996;2584-2589.
52. Raybin D., Flavin M. An enzyme tyrosylation α-tubulin and its role in microtubule assembly. Biochem Biophys Res Commun. 65:1975;1088-1095.
53. Sangrajrang S., Denoulet P., Millot G., Tatoud R., Podgorniak M., Tew K.D., Calvo F., Fellous A. Estramustine resistance correlates with tau overexpression in human prostatic carcinoma cells. Int J Cancer. 77:1998;626-631. a.
54. Sangrajrang S., Denoulet P., Laing N.M., Tatoud R., Millot M. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem Pharmacol. 55:1998;325-331. b.
55. Seidman A.D., Scher H.I., Petrylak D., Dershaw D., Curley T. Estramustine and vinblastine. use of prostate specific antigen as a clinical trial and point for hormone refractory prostatic cancer J Urol. 147:1992;931-934.
56. Sheridan V.R., Speicher L.A., Tew K.D. The effects of estramustine on metaphase and anaphase in DU145 prostatic carcinoma cells. Eur J Cell Biol. 54:1991;268-276.
57. Slobada R.D., Rudolphm S.A., Rosenbaum J.L., Greengard P. Cyclic AMP-dependent endogenous phosphorylation of a microtubule-associated protein. Proc Natl Acad Sci USA. 72:1975;177-181.
58. Speicher L.A., Sheriden V.R., Godwin A.K., Tew K.D. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype. Br J Cancer. 64:1991;267-273.
59. Speicher L.A., Barone L.A., Chapman A.E., Hudes G.R., Laing N., Smith C.D., Tew K.D. P-glycoprotein binding and modulation of the MDR phenotype by estramustine. J Nalt Cancer Inst. 86:1994;688-694. a.
60. Speicher L.A., Laing N., Barone L., Robbins J.D., Seamon K.B., Tew K.D. Interaction of estramustine photoaffinity analog with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol. 46:1994;866-872. b.
61. Stearns M., Tew K.D. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci. 89:1988;331-342.
62. Sullivan K.F., Cleveland D.W. Identification of conserved isotype-defending variable region seguences for four vertebrate β tubulin polypeptide classes. Proc Natl Acad Sci USA. 83:1986;4237-4331.
63. Trinczek B., Biernat J., Baumann K., Mandelkow E.M., Mandelkow E. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell. 6:1995;1887-1902.
64. Valbo C., Bergenheim T., Bergh A., Grankvist K., Henriksson R. DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain. suggesying an apoptotic cell death Br J Cancer. 71:1995;717-720.
65. Valbo C., Bergenheim A.T., Henriksson R. Apoptosis induced in malignant glioma by estramustine in the clinical situation (abstract). J Neurooncol. 30:1996;106.
66. Von Schoultz E., Lundlad D., Bergh J., Grankvist K., Henriksson R. Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines. Br J Cancer. 58:1988;326-329.
67. Von Schoultz E., Grankvist K., Gustavsson H., Henriksson R. Effects of estramustine on DNA and cell membrane in malignant glioma cells. Acta Oncol. 30:1991;719-723.
68. Von Schoultz E., Carlström K., Henriksson R., Lagerlof B., Hansson J. Estramustine-binding protein in primary tumors and metastasis of malignant melanoma. Melanoma Res. 4:1994;401-405.
69. Watanabe A., Hasegawa M., Suzuki M., Takio K., Morishima-Kawashima M., Titani K., Arai T., Kpsik K., Ihara Y. In vivo phosphorylation sites in fetal and adult rat tau. J Biol Chem. 34:1993;25721-25727.
70. Weingarten M.D., Lockwood A.H., Hwo S.Y., Kirschner M.W. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA. 72:1975;1858-1862.
71. Widmark A., Damber J.-E., Bergh A., Henriksson R. Estramustine potentiates the effects of irradiation on the dunning (R3327) ret prostatic adenocarcinoma. Prostate. 24:1994;79-83.
72. Wilson, L., Jordan, M.A., 1994. In: Hyams J.L., Lloyd H.A. (Eds.), Microtubules. Wiley-Liss, New York, pp. 59-83.
73. Yoshida D., Piepmier J., Weinstein M. Estramustine sensitizes human glioblastoma cells to irradiation. Cancer Res. 54:1994;1415-1417.